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Abstract
Background: β-alanine (βA) supplementation has been shown to increase intramuscular carnosine content and
subsequent high-intensity performance in events lasting < 4 minutes (min), which may be dependent on total, as
opposed to daily, dose. The ergogenic effect of βA has also been demonstrated for 2000-m rowing performance
prompting interest in whether βA may be beneficial for sustained aerobic exercise. This study therefore investigated
the effect of two βA dosing strategies on 30-min rowing and subsequent sprint performance.
Methods: Following University Ethics approval, twenty-seven healthy, male rowers (age: 24 ± 2 years; body-height: 1.81
± 0.02m; body-mass: 82.3 ± 2.5 kg; body-fat: 14.2 ± 1.0%) were randomised in a double-blind manner to 4 weeks of: i) βA
(2.4 g·d− 1, βA1); ii) matched total βA (4.8 g on alternate days, βA2); or iii) cornflour placebo (2.4 g·d− 1, PL). Participants
completed a laboratory 30-min rowing time-trial, followed by 3x30-seconds (s) maximal sprint efforts at days 0, 14 and
28 (T1-T3). Total distance (m), average power (W), relative average power (W·kg− 1), cardio-respiratory measures and
perceived exertion were assessed for each 10-min split. Blood lactate ([La-]b mmol·L
− 1) was monitored pre-post time-trial
and following maximal sprint efforts. A 3-way repeated measures ANOVA was employed for main analyses, with
Bonferonni post-hoc assessment (P≤ 0.05).
Results: Total 30-min time-trial distance significantly increased from T1-T3 within βA1 only (7397 ± 195m to 7580 ± 171m,
P= 0.002, ƞp2 = 0.196), including absolute average power (194.8 ± 18.3W to 204.2 ± 15.5W, P= 0.04, ƞp2 = 0.115) and
relative average power output (2.28 ± 0.15W·kg− 1 to 2.41 ± 0.12W·kg− 1, P= 0.031, ƞp2 = 0.122). These findings were
potentially explained by within-group significance for the same variables for the first 10min split (P≤ 0.01), and for distance
covered (P = 0.01) in the second 10-min split. However, no condition x time interactions were observed. No significant
effects were found for sprint variables (P > 0.05) with comparable values at T3 for mean distance (βA1: 163.9 ± 3.8m; βA2:
161.2 ± 3.5m; PL: 162.7 ± 3.6m), average power (βA1: 352.7 ± 14.5W; βA2: 342.2 ± 13.5W; PL: 348.2 ± 13.9W) and lactate
(βA1: 10.0 ± 0.9mmol·L− 1; βA2: 9.2 ± 1.1mmol·L− 1; PL: 8.7 ± 0.9mmol·L− 1).
Conclusions: Whilst daily βA may confer individual benefits, these results demonstrate limited impact of βA (irrespective of
dosing strategy) on 30-min rowing or subsequent sprint performance. Further investigation of βA dosage > 2.4 g·d− 1 and/
or chronic intervention periods (> 4–8weeks) may be warranted based on within-group observations.
Keywords: Beta-alanine, Rowing, Endurance, Exercise performance, Nutrition
* Correspondence: justin.roberts@anglia.ac.uk
1Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,
Cambridge, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Beasley et al. Journal of the International Society of Sports Nutrition           (2018) 15:59 
https://doi.org/10.1186/s12970-018-0266-3
Introduction
β-alanine (βA) first gained popularity within the
athletic population during the mid-2000’s following
the inaugural work of Harris and colleagues [1].
Numerous research has since demonstrated that βA
supplementation (1.6–6.4 g·day− 1 for ≥28 days)
augments the naturally occurring histidine dipeptide,
carnosine (β-alanyl-L-histidine) within human muscle
tissue [2–5]. As carnosine acts as a physico-chemical
buffering agent (with an imidazole ring pKa of 6.83,
and relative similarity to intracellular pH (6.5) [6–8]),
βA supplementation was recently reported as produ-
cing small, yet significant performance improvements
(effect size: 0.210; 95% CI: 0.057, 0.362) across a
range of short (60–240 s) duration events [9] includ-
ing cycling sprint performance [10], judo bouts [11],
800 m sprinting [12] and 1000 m rowing splits [13] in
club-level through to well training men.
Beyond these short duration (60–240 s) bouts the
magnitude of improvement appears to diminish. How-
ever, a recent meta-analysis based on 40 individual stud-
ies involving 1461 participants indicated that the
predominant use of incremental tests in many studies
may potentially bias this finding based on assessment of
exercise capacity as opposed to aerobic performance [9].
Additionally, in a recent International Society of Sports
Nutrition (ISSN) Position Stand, Trexler et al [14] noted
an apparent dearth of βA research investigating perform-
ance during endurance events (> 25-min), with inference
that βA may ergogenically support training adaptations to
sustained efforts typically employed in aerobically domi-
nated events [15–18].
Specific to rowing, previous research has highlighted a
significant correlation between muscle carnosine content
and performances over multiple distances (100, 500,
2000 and 6000m) [19]. It is therefore feasible that
short-term βA supplementation could support pro-
longed training bouts or enhance > 2000 m performance,
particularly in non-elite rowers or those with lower
initial muscle carnosine levels [20–22]. With the high
levels of acidity brought about as a bi-product of anaer-
obic glycolysis, and subsequent elevated blood lactate
production observed in competitive rowers, the buffer-
ing potential of carnosine could facilitate higher power
output throughout an endurance bout/race, or as part of
a final sprint [19, 23]. However, such hypotheses rely on
assumptions that perhaps over-simplify the mechanistic
effects of βA, including improved calcium sensitivity
[24], enhanced antioxidant capacity and reduced oxida-
tive damage [25, 26].
In terms of dosing strategies, βA intakes from 1.6
g·day− 1 to 12 g·day− 1 [2, 27] for ≥2-weeks have been
shown to significantly increase muscle carnosine content
(with typically recommended levels of 2–6 g·day− 1 [1, 4,
7, 10, 28]). However, research has also highlighted that
muscle carnosine content correlates significantly with
total dose (grams) of βA consumed [2, 29] irrespective
of baseline carnosine levels or daily intake. This raises
an important question as to whether βA needs to be
consumed daily, or whether ergogenic benefits are based
on total dose provided in a given timeframe [2]. This is
particularly relevant considering a recent survey in
which 61% of Australian team sport athletes used βA as
part of their training, yet only 35% understood the
mechanistic benefits, and 50% consumed less than half
of the commercially recommended dose [30].
The aim of the current study was therefore to assess
the efficacy of two βA strategies (daily versus alternate
day intake for 4 weeks) on 30-min rowing time-trial per-
formance and subsequent anaerobic sprint bouts in
healthy, male rowers. It was hypothesised that βA would
significantly enhance endurance performance irrespect-
ive of dosing strategy.
Materials/ methods
Study design and participants
A randomised, double-blind, placebo controlled, paral-
lel design was employed for this study. The study was
conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by the Faculty
of Science and Technology Ethics Committee, Anglia
Ruskin University (Project Number: FST/FREP/15/591).
A priori sample size using G*power software (α = 0.05
and 1-β = 0.90) based on performance data from
Ducker et al. [13] estimated a total sample population
of 27 participants. Participants were required to be
healthy, male rowers with > 6 months training experi-
ence (including familiarity with 30- min time-trial
sessions), and actively training > 3 times per week at
the point of inclusion.
Informed consent was obtained from all individual
participants prior to study inclusion. All participants
satisfactorily completed a health screen questionnaire,
and had no known history of blood related disorders,
cardiovascular or metabolic abnormalities; or recent viral
infections or injuries, which would prevent them from
maintaining habitual training sessions or taking part in
laboratory time-trials. Individuals at risk of lowered
baseline carnosine, as a result of dietary restriction of
animal products (vegan/vegetarians), were excluded
from participation [31]. All participants were required
not to be taking any medication / supplementation in
the previous 3months which could interfere with the
study parameters, and in particular, complete abstinence
(> 6 months) from βA-containing supplements specific-
ally due to the slow washout rate previously reported for
muscle carnosine content [32, 33]. Thirty male individ-
uals volunteered for study inclusion. However, 3 were
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excluded from final analyses due to non-compliance
with protocol requirements. Participant characteristics
are displayed in Table 1.
Procedures
All testing took place within the Cambridge Centre for
Sport and Exercise Sciences, Human Physiology Labora-
tory, Anglia Ruskin University, Cambridge under thermal
neutral conditions (temperature:17.1–19.3 °C; humidity:
20–38%; barometric pressure: 993–1028mbar). Following
pre-familiarization with the laboratory equipment and test
protocol, participants were required to attend the labora-
tory on 3 occasions across the intervention period (days 0,
14 and 28; T1-T3) at the same time of day for each
participant to minimise diurnal variance. Participants were
instructed to avoid strenuous exercise, and refrain from
consuming caffeinated or alcohol containing products at
least 24 hours prior to each laboratory visit. Participants
were requested to arrive acutely fasted (i.e. no food within
3 hours of assessment and maintain habitual hydration
patterns) with last consumption of fluid (~ 0.5 L water) 1
hour prior to assessment to standardise procedures.
Upon arrival, body mass (Seca 780, Hamburg, Germany),
height (Seca 200 stadiometer, Hamburg, Germany) and
estimated body composition (4-site skinfold measures in
triplicate) were assessed by the same researcher. Following
a 5-min seated period, 2-min baseline expired air samples
were collected via the Douglas bag method [34] and ana-
lysed for percentage O2 and CO2, using a Servoflex
MINIMP 5200 gas analyser (Servomex Group Ltd., Crow-
borough, UK). Total Douglas bag volume was measured
using a dry gas meter (Harvard Apparatus, Holliston,
USA), with sample temperature recorded during volume
measurement. Heart rate (HR) was recorded via
radio-telemetry (T-31, Polar Electro Ltd., Kempele,
Finland), and 20 μl capillarised fingertip blood samples
were collected for analysis of blood lactate [La−]b (Biosen
C_Line, EKF Diagnostics, Cardiff, UK).
Rowing ergometer time trials (TT)
All time-trials were conducted on the same Concept 2
air braked rowing ergometer (Concept 2, Nottingham,
UK) with resistance set at 5 for standardisation. Partici-
pants undertook a self-paced, continuous warm-up at
100W for 5-min, after which the unit display was modi-
fied to display time remaining to minimise extraneous
influences on pacing strategy [35]. Participants were
instructed to row for maximal distance in 30- min at
self-selected pace. To minimise effects of data collection
on performance, expired air, rated perceived exertion
(RPE [36]) and HR were assessed during the final minute
of each 10-min split; along with split distance covered
(m) and mean power output (W).Verbal encouragement
was provided by the same tester at the end of each col-
lection period in a standard manner. End-point [La−]b
was assessed following the final collection period only.
Sprint efforts post-TT
Following a standardised 5-min inactive rest period,
participants completed three 30-s maximal sprint efforts
with 60-s inactive recovery in between. [La−]b, RPE and
performance data (distance rowed (m), average power
(W)) were recorded on completion of each sprint. At the
mid-point of each sprint, standardised verbal encourage-
ment was given to all participants to promote maximal
engagement.
Supplemental treatments
Participants were randomly assigned (using a random
number generator – https://www.randomizer.org/) in a
double-blind manner to 4 weeks of: i) crystalline βA (2.4
g·d− 1 Bulk Powders®, UK; βA1); ii) matched total βA (4.8 g
on alternate days, βA2); or iii) cornflour placebo (2.4 g·d− 1,
PL). These daily doses were selected to minimise the risk
of paraesthesia and thus the potential to affect the double
blinding process. Furthermore, the matched average daily
dose of 2.4 g∙day− 1 was deemed appropriate given previous
research demonstrating increased muscle carnosine con-
centrations at lower daily doses (1.6 g∙day− 1) [2]. All prod-
ucts were manually weighed under laboratory conditions
for accuracy and capsulated in size 00 capsules (hydroxy-
propyl methylcellulose). Once weighed all capsules were
placed in food safe containers before an independent
researcher recorded and randomized all batches to ensure
double blinding procedures. All participants received
capsules on a 14-day basis, along with a daily adherence
diary to monitor compliance. To limit both the occurrence
and severity of potential paraesthesia symptoms, standard
instructions were provided to participants to consume one
(800mg) capsule daily with breakfast before repeatedly
consuming (800mg) capsules every 3 hours until required
dosage was met, in accordance with previous research [37,
38]. Upon completion of each 14-day period participants
Table 1 Participant characteristics and baseline measurements
Variable All Participants
(n = 27)
βA1
(n = 9)
βA2
(n = 9)
PL
(n = 9)
Age (years) 24 ± 5 20 ± 6 24 ± 5 23 ± 1
Body- height (m) 1.81 ± 0.01 1.81 ± 0.02 1.81 ± 0.02 1.82 ± 0.02
Body-mass (kg) 82.4 ± 1.4 84.4 ± 3.1 80.3 ± 1.8 82.4 ± 2.6
Body-fat (%) 14.2 ± 0.6 15.1 ± 1.0 12.7 ± 1.1 14.8 ± 0.6
Fat-free mass (kg) 70.6 ± 1.2 71.5 ± 2.3 70.0 ± 1.6 70.3 ± 2.4
Experience (yrs) 2.0 ± 0.3 1.7 ± 0.5 2.0 ± 0.4 2.3 ± 0.6
Table 1 outlines baseline participant characteristics. Data are presented as M ±
SE. βA1 daily beta-alanine strategy, βA2 alternate day strategy, PL placebo. No
significant between-group differences reported.
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were instructed to return any remaining capsules as a sec-
ondary measure of compliance.
Dietary intake
Prior to baseline measures, and throughout the inter-
vention, participants were requested to maintain habit-
ual dietary intake and exercise patterns, and record
using standard food/activity diaries (following individ-
ual guidance in diary collation, with emphasis on meal
content, portion size and weight and fluid intake). In
particular, participants were requested to refrain from
introducing atypical foods during the intervention
period. Diaries were comprehensively checked by the
research team at each visit, with dietary analyses under-
taken using Nutritics software (version 3.74 profes-
sional edition, Nutritics Ltd., Co. Dublin, Ireland). No
differences were reported between groups for macronu-
trients and/or energy intake (Table 2), demonstrating
general dietary compliance prior to testing sessions.
Statistical analyses
Statistical analyses were performed using SPSS (v24,
Chicago, USA). Normal distribution of data was assessed
via a Shapiro-Wilks test [39]. A 3-way repeated measures
ANOVA was employed for main analyses (including effect
size (partial eta squared; ηp2)), with Bonferonni post-hoc
assessment where applicable. Where pertinent, a one-way
ANOVA with Bonferroni post hoc assessment was utilised
to evaluate within treatment effects (e.g. baseline variables
and resting measures). An alpha level of ≤0.05 was
employed for statistical significance. Data are reported as
means ± SE.
Results
Baseline characteristics and resting measures
Intervention groups were matched for age (yrs), rowing
experience (yrs), body-height (m), body-mass (kg) and
body-fat (%) at baseline (Table 1). Non significant differ-
ences (P > 0.05) were reported between groups for base-
line resting HR (b·min− 1) (βA1: 66 ± 3, βA2: 62 ± 3, PL:
60 ± 2), [La−]b (mmol·L
− 1) (βA1: 1.4 ± 0.1, βA2:
1.4 ± 0.1, PL: 1.3 ± 0.1), absolute VO2 (L·min
− 1) (βA1:
0.34 ± 0.04, βA2: 0.34 ± 0.02, PL: 0.37 ± 0.03) or relative
VO2 (ml·kg
− 1·min− 1) (βA1: 4.08 ± 0.40, βA2:
4.11 ± 0.24, PL: 4.28 ± 0.28).
Time-trial performance measures
Overall distance
Data for distance rowed (m) during the 30-min time
trial are shown as absolute a) and relative b) values
in Fig. 1. No group x time interactions were shown
for overall 30-min time trial performance (F = 1.50,
P = 0.22, ηp2 = 0.11). A significant effect was shown
for time only (F = 5.87, P = 0.005 ηp2 = 0.20), with
βA1 distance increasing from 7397 ± 195 m at T1 to
7580 ± 171 m by T3 only (P = 0.002, Fig. 1). This
represented a 2.45% absolute improvement in per-
formance within-group only. When expressed rela-
tively (T1-T3), despite a 2.60% increase in distance
covered (183 ± 52 m) with βA1, and a 1.50%
increase in distance covered (107 ± 48 m) with βA2,
no significant between group differences were noted
(F = 1.91, P = 0.17).
Power: Weight
Similarly, mean power significantly increased for time
only (F = 3.11, P = 0.05, ηp2 = 0.12) with βA1 from
194.8 ± 18.3W (T1) to 204.2 ± 15.5 (T3) (P = 0.04).
No differences were reported within group for βA2
(200.3 ± 9.8W (T1) to 208.8 ± 8.0W (T3); P > 0.05)
or PL (173.0 ± 13.8W (T1) to 174.8 ± 13.7W (T3);
P > 0.05). When adjusted for body-mass, average
power output expressed as a) absolute and b) relative
change is shown in Fig. 2. A significant time effect
was observed for changes in average power to weight
(W·kg− 1) between T1 and T3 (F = 3.35, P = 0.04, ηp2
= 0.12) for βA1 only (2.28 ± 0.15W·kg− 1 to
2.41 ± 0.12; P = 0.03). A significant between group main
effect was reported (F = 3.53, P = 0.04, ηp2 = 0.12), with
post-hoc analysis indicating an overall difference between
βA2 and PL only (P = 0.04). However, no group x time in-
teractions were shown for absolute changes in average
power to weight ratio (F = 1.12, P = 0.36, ηp2 = 0.09).
When data was expressed as relative change in average
Table 2 Mean group dietary intake across the intervention
period (T1-T3)
Variable βA1 βA2 PL
Energy (kcal.kg-1.d–1)
T1 27.73 ± 1.49 25.32 ± 1.23 29.00 ± 1.88
T2 28.34 ± 1.25 23.00 ± 1.16 26.46 ± 1.99
T3 25.40 ± 2.09 25.78 ± 1.19 28.35 ± 1.63
Protein (g kg-1.d–1)
T1 1.91 ± 0.33 1.69 ± 10.15 1.84 ± 0.26
T2 1.71 ± 0.23 1.63 ± 0.11 1.82 ± 0.22
T3 1.85 ± 0.34 1.85 ± 0.18 1.82 ± 0.32
Carbohydrate (g.kg-1.d–1)
T1 2.64 ± 0.12 2.20 ± 0.16 2.69 ± 0.32
T2 2.95 ± 0.26 2.22 ± 0.22 2.44 ± 0.33
T3 2.23 ± 0.14 2.26 ± 0.18 2.64 ± 0.34
Fat (g.kg-1.d–1)
T1 1.02 ± 0.11 1.06 ± 0.13 1.17 ± 0.12
T2 0.97 ± 0.14 0.82 ± 0.09 1.06 ± 0.18
T3 0.97 ± 0.12 1.02 ± 0.11 1.13 ± 0.17
Table 2 shows relative dietary intake for both group and time. No significant
differences reported within or between groups.
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power, no significant between group differences were
observed (F = 1.31, P = 0.29); despite small improvements
of 0.13 ± 0.06W·kg− 1 for βA1 and 0.11 ± 0.05W·kg− 1 for
βA2, in contrast to negligible changes of 0.01 ± 0.06
W·kg− 1 for PL.
30-min time trial- average physiological variables and
perceived effort
Average HR significantly increased by T3 (F = 4.22,
P = 0.02, ηp2 = 0.15) for βA1 only (175 ± 3 to
180 ± 2 b·min− 1; P = 0.01), however RPE was main-
tained throughout the intervention (average RPE: 7.7 ± 0.2
(T1), 7.8 ± 0.2 (T2), 7.8 ± 0.3 (T3) P > 0.05). In contrast,
average RPE significantly increased by T3 (F = 5.12,
P = 0.01, ηp2 = 0.18) for both βA2 (7.1 ± 0.5 (T1) to
7.7 ± 0.4 (T3); P = 0.04) and PL (6.5 ± 0.4 (T1) to
7.3 ± 0.03 (T3); P = 0.01). Average VO2 was main-
tained across all trials with no group x time interac-
tions reported (βA1: 3.12 ± 0.12 L·min− 1 (T1) to
3.14 ± 0.10 (T3); βA2: 3.17 ± 0.10 L·min− 1 (T1) to
3.24 ± 0.14 (T3); PL: 2.93 ± 0.13 L·min− 1 (T1) to
2.86 ± 0.14 (T3); P > 0.05).
30-min time trial- Split data (0–10 min)
No group x time interactions were shown for overall
0-10 min time trial performance (F = 1.17, P = 0.34,
ηp2 = 0.089; Table 3). A significant effect was shown
for time only (F = 8.27, P = 0.001, ηp2 = 0.256), with
βA1 significantly increasing between T1-T2 (P = 0.03),
T1-T3 (P = 0.004) representing a 3.65% (T1-T2) and
4.52% (T1-T3) distance increase, respectively. Like-
wise, βA2 also increased distance covered significantly
by 2.55% from T2-T3 (P = 0.01). Accompanying these
effects for distance, time effects (F = 4.77, P = 0.01,
ηp2 = 0.166) for absolute power was observed in βA1
only between T1-T2 (P = 0.03) and T1-T3 (P = 0.01).
These represented a 14.04 and 14.61% increase in
watts, respectively. Time effects (F = 5.37, P = 0.01,
ηp2 = 0.166) for power to weight was observed in βA1
only, between T1-T2 (P = 0.02) and T1-T3 (P = 0.01).
A
B
Fig. 1 demonstrates effect of beta-alanine (βA) interventions on a) absolute and b) relative 30-min rowing time trial distance. Abbreviations: βA1
– daily intervention; βA2 – alternate day; PL – placebo. * represents significant difference, from T1, within group only
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AB
Fig. 2 demonstrates effect of beta-alanine (βA) interventions on a) absolute and b) relative power to weight during the 30-min rowing time trial.
Abbreviations: βA1 – daily intervention; βA2 – alternate day; PL – placebo. * represents significant difference, from T1, within group only. #
represents overall group difference to PL (P = 0.04)
Table 3 Average performance, cardio-respiratory and perceived exertion data for initial 10-min split (0–10 min) during the 30-min TT
βA1 βA2 PL
Variable T1 T2 T3 T1 T2 T3 T1 T2 T3
Distance (m) 2426 ± 87 2503 ± 56# 2525 ± 61* 2483 ± 45 2481 ± 40 2544 ± 42b 2318 ± 89 2336 ± 71 2363 ± 74
Power (W) 185.3 ± 21.1 203.1 ± 15.5# 204.4 ± 16.4* 197.2 ± 10.6 197.9 ± 9.3 209.2 ± 9.2 159.8 ± 20.1 161.7 ± 15.5 165.7 ± 17.0
Power (W·kg− 1) 2.16 ± 0.19 2.38 ± 0.12# 2.41 ± 0.14* 2.47 ± 0.15 2.48 ± 0.14 2.62 ± 0.13 1.93 ± 0.22 1.94 ± 0.17 1.99 ± 0.19
HR (b·min− 1) 164 ± 4 171 ± 4 172 ± 3* 159 ± 5 165 ± 5 166 ± 4* 159 ± 7 161 ± 6 159 ± 6
RPE 6.1 ± 0.4 6.3 ± 0.2 6.1 ± 0.5 5.1 ± 0.6 5.1 ± 0.4 6.2 ± 0.5 4.4 ± 0.5 4.9 ± 0.6 5.0 ± 0.5
VE (L·min
− 1) 78.6 ± 6.4 81.6 ± 2.8 84.0 ± 4.0 76.4 ± 2.7 77.2 ± 2.6 77.8 ± 2.2 71.8 ± 4.4 73.8 ± 4.4 72.5 ± 3.7
VO2 (L·min
− 1) 3.03 ± 0.26 3.07 ± 0.16 3.23 ± 0.23 2.90 ± 0.15 3.16 ± 0.16 3.13 ± 0.17 2.65 ± 0.18 2.50 ± 0.21 2.47 ± 0.24
VCO2 (L·min
− 1) 3.05 ± 0.26 3.04 ± 0.16 3.12 ± 0.20 3.13 ± 0.20 2.95 ± 0.15 3.18 ± 0.21 2.89 ± 0.27 2.76 ± 0.22 2.74 ± 0.19
RER 0.96 ± 0.02 0.91 ± 0.04 0.89 ± 0.05 0.93 ± 0.05 0.90 ± 0.04 0.82 ± 0.04 0.89 ± 0.03 0.91 ± 0.03 0.95 ± 0.02
Data in Table 3 refers to the first 10-min split of the 30-min TT. Time points denoted by T1-T3. Abbreviations: HR heart rate, RPE rating of perceived exertion, VE
minute ventilation, VO2 absolute oxygen uptake, VCO2 absolute carbon dioxide, RER respiratory exchange ratio. # = significantly different T1-T2 within group only
(P < 0.03); * = significant difference within group T1-T3 (P < 0.05); b = significant difference T2-T3 within group only (P = 0.01)
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These represented a 6.20 and 6.75% increase in
W·kg− 1, respectively.
A significant effect was observed for changes in HR
(b·min− 1) between T1 and T3 (F = 4.992, P = 0.01, ηp2
= 0.17) for βA1 (164 ± 4 to 172 ± 3 b·min− 1; P = 0.02) and
βA2 (159 ± 5 b·min− 1 to 166 ± 4; P = 0.05), but not PL
(P > 0.05). In contrast, average RPE (F = 1.607, P = 0.19,
ηp2 = 0.118), VE (F = 0.410, P = 0.41, ηp
2 = 0.036), VO2
(F = 1.398, P = 0.25, ηp2 = 0.104), VCO2 (F = 0.384, P = 0.82,
ηp2 = 0.031) and RER (F = 2.234, P = 0.08, ηp2 = 0.157)
were maintained across all trials with no significant
interactions reported.
30-min time trial- Split data (11–20 min)
No group x time interactions were shown during the
second 10-min split (F = 0.694, P = 0.60, ηp2 = 0.055;
Table 4). Within group however a significant time effect
was demonstrated (F = 3.987, P = 0.03, ηp2 = 0.257), with
βA1 increasing distance rowed by 54 ± 14 m between
T1-T3 (P = 0.01). Other performance variables such as
absolute power (F = 1.283, P = 0.29, ηp2 = 0.051) and
power to weight (F = 1.177, P = 0.32, ηp2 = 0.073) failed to
reach significance overall. Average HR (F = 1.893, P = 0.16,
ηp2 = 0.073), VE (F = 0.959, P = 0.39, ηp
2 = 0.038), VO2
(F = 0.780, P = 0.46, ηp2 = 0.031), VCO2 (F = 1.115, P = 0.34,
ηp2 = 0.044), RPE (F = 2.971, P = 0.07, ηp2 = 0.205), and
RER (F = 0.079, P = 0.93, ηp2 = 0.003) were maintained
across all trials with no significant interactions reported.
30-min time trial- Split data (21–30 min)
No group x time interactions were shown for overall 21–
30min time trial distance covered (F = 2.027, P = 0.21,
ηp2 = 0.144; Table 5). Likewise, no effects were shown for
time (F = 1.594, P = 0.12, ηp2 = 0.062) in distance covered
or other performance variables (P > 0.05). Average HR
(F = 0.841, P = 0.41, ηp2 = 0.034), VE (F = 0.959, P = 0.39,
ηp2 = 0.038), VO2 (F = 1.649, P = 0.20, ηp
2 = 0.064), VCO2
(F = 1.850, P = 0.18, ηp2 = 0.070) RPE (F = 2.882, P = 0.66,
ηp2 = 0.107) and RER (F = 0.803, P = 0.0.76, ηp2 = 0.032)
were maintained across trials with no significant group x
time interactions reported.
Overall sprint performance
No significant between-group effects existed at T1 with
all groups rowing 166.0 ± 2.5 m (F = 2.325, P = 0.07, ηp2
= 0.162; Table 6). Following treatment with their respect-
ive intervention, no significant group x time (F = 2.325,
P = 0.07, ηp2 = 0.162), or time (F = 1.936, P = 0.16,
ηp2 = 0.075) effects were observed at any time-point
for distance covered. Likewise, power (F = 1.961, P = 0.15,
ηp2 = 0.076), power to weight (F = 1.251, P = 0.30,
ηp2 = 0.050), HR (F = 1.241, P = 0.30, ηp2 = 0.049),
RPE (F = 3.920, P = 0.26, ηp2 = 0.140) and [La-]b (F = 0.759,
P = 0.46, ηp2 = 0.032) failed to reach significance.
Discussion
The aim of the current randomised controlled trial was
to observe the effects of two separate, 28-day, βA dosing
strategies (matched for total overall dose), on 30-min
rowing time trial and subsequent anaerobic sprint
performance. A recent 2018 ISSN Position Stand [40]
stated there is ‘strong evidence’ to support the efficacy of
βA as an ergogenic aid, with research demonstrating
positive influences over short duration performance
[11–13] and capacity [3] measures alike. However, the
primary finding of this study indicates that βA does not
appear to offer significant benefits to sustained endur-
ance performance, as assessed via a 30-min time trial
when compared to placebo. These findings concur with
an earlier 2015 ISSN Position Stand [14] indicating that
βA consumption “does not demonstrate a consistent
positive effect” on events lasting beyond a 25-min time-
frame. It is, however, noteworthy that within-group
improvements were observed for mean distance covered,
average power and average power to weight ratio when
participants consumed βA daily, increasing by 2.6, 14.6
Table 4 Average performance, cardio-respiratory and perceived exertion data for mid 10-min split (11–20 min) during the 30 min TT
βA1 βA2 PL
Variable T1 T2 T3 T1 T2 T3 T1 T2 T3
Distance (m) 2449 ± 67 2478 ± 56 2502 ± 60* 2458 ± 35 2477 ± 36 2497 ± 34 2365 ± 63 2373 ± 47 2362 ± 60
Power (W) 189.8 ± 16.2 199.9 ± 14.3 201.4 ± 16.7 197.6 ± 10.2 199.4 ± 9.1 201.1 ± 7.9 168.8 ± 14.3 168.7 ± 11.9 169.4 ± 14.7
Power (W·kg− 1) 2.23 ± 0.13 2.35 ± 0.10 2.37 ± 0.14 2.47 ± 0.15 2.50 ± 0.14 2.52 ± 0.13 2.04 ± 0.14 2.04 ± 0.14 2.03 ± 0.14
HR (b·min− 1) 174 ± 4 177 ± 3 178 ± 2 169 ± 4 173 ± 53 172 ± 4 171 ± 5 170 ± 4 170 ± 4
RPE 7.7 ± 0.3 7.7 ± 0.2 7.6 ± 0.3 6.9 ± 0.7 7.0 ± 0.6 7.7 ± 0.4 6.2 ± 0.5 6.9 ± 0.4 7.4 ± 0.4
VE (L·min
− 1) 88.8 ± 6.7 91.0 ± 4.0 88.6 ± 5.3 83.5 ± 2.5 78.4 ± 3.9 82.5 ± 2.8 83.8 ± 2.2 78.5 ± 3.4 80.1 ± 3.1
VO2 (L·min
− 1) 3.28 ± 0.26 3.38 ± 0.23 3.60 ± 0.44 3.17 ± 0.13 3.14 ± 0.14 3.10 ± 0.16 3.07 ± 0.13 2.69 ± 0.10 3.00 ± 0.19
VCO2 (L·min
− 1) 3.20 ± 0.22 3.30 ± 0.12 3.26 ± 0.20 3.30 ± 0.16 2.97 ± 0.14 3.20 ± 0.19 3.29 ± 0.25 2.98 ± 0.25 3.11 ± 0.25
RER 1.04 ± 0.02 1.02 ± 0.01 0.99 ± 0.03 0.97 ± 0.04 0.97 ± 0.02 0.97 ± 0.04 1.00 ± 0.02 1.03 ± 0.01 1.04 ± 0.03
Data in Table 4 refers to the second 10-min split of the 30-min TT. Time points denoted by T1-T3. HR heart rate, RPE rating of perceived exertion, VE minute
ventilation, VO2 absolute oxygen uptake, VCO2 absolute carbon dioxide, RER respiratory exchange ratio. * = significant difference within group T1-T3 (P = 0.01)
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and 14.9%, respectively over the intervention period.
This may likely be the result of improved effort (distance
covered and power output (including relative to mass))
in the first 10-min split. In the second 10-min split,
whilst a within group increase was observed for distance
covered (T1-T3) for βA1, power output did not signifi-
cantly change, potentially indicating a diminishing effect
with time trial duration.
The findings from the current study support previ-
ous research on 10-km running performance [41],
whereby a mean reduction in time taken to complete
10-km (Pre = 3441 ± 327, Post = 3209 ± 271 s) was
observed within the βA group only. However, it
should be noted that the participants mean baseline
10-km time was a conservative 57.35 min, suggesting
that results may have been confounded by the experi-
ence of the runners. Nonetheless, beyond this study
there exists a lack of results during comparable (≥30- min)
protocols. More specifically, the current split data support
Saunders and colleague’s meta-analysis in suggesting that
the strength of evidence supporting βA’s efficacy does not
extend to longer duration (> 10-min) events [9] (despite
the fact that many athletes use βA for endurance-based
events). This same review noted that findings were poten-
tially confounded by an absence of research investigating
longer duration events [14] and the predominant use of
incremental tests [9], two issues the current study
attempted to circumvent. Therefore, whilst these data
could be interpreted as providing preliminary support for
βA’s potential to facilitate small scale improvements, when
compared to a placebo there appears to be no significant
benefit of consuming βA in the short term for longer
duration aerobic exercise.
Regarding the anaerobic sprint data, no significant inter-
action effects were observed for any variables. This was
unexpected as previously Suzuki et al. [42] noted a strong
positive correlation between muscle carnosine concentra-
tion and Wingate performance. Likewise, rowers have
exhibited greater muscle carnosine concentration and
buffering capacity when compared with both marathoners
and non-trained controls [43] . Therefore, it had been
hypothesised that facilitating elevated muscle carnosine
via βA consumption could have a significant effect on
rowing sprint performance. One explanation for the lack
of effect in the current study may have been the different
exercise modality (rower vs cycle) employed. When
Table 5 Average performance, cardio-respiratory and perceived exertion data for final 10-min split (21–30 min) during the 30-min
TT, including endpoint [La-]b
βA1 βA2 PL
Variable T1 T2 T3 T1 T2 T3 T1 T2 T3
Distance (m) 2533 ± 49 2543 ± 43 2552 ± 56 2526 ± 34 2537 ± 39 2534 ± 39 2503 ± 35 2431 ± 44 2503 ± 35
Power (W) 213.4 ± 16.6 206.0 ± 12.1 206.7 ± 14.3 206.2 ± 9.4 207.0 ± 9.5 217.9 ± 10.9 193.2 ± 9.2 180.2 ± 10.9 190.8 ± 11.0
Power (W·kg−1) 2.51 ± 0.12 2.43 ± 0.08 2.44 ± 0.11 2.58 ± 0.13 2.60 ± 0.14 2.72 ± 0.14 2.34 ± 0.09 2.17 ± 0.11 2.30 ± 0.10
HR (b.min− 1) 185 ± 5 189 ± 3 190 ± 3 183 ± 3 183 ± 4 182 ± 3 185 ± 3 184 ± 2 185 ± 3
RPE 9.3 ± 0.2 9.4 ± 0.2 9.7 ± 0.2 9.2 ± 0.3 9.2 ± 0.3 9.3 ± 0.3 8.8 ± 0.4 9.2 ± 0.3 9.6 ± 0.2
VE (L·min
−1) 100.4 ± 3.5 105.0 ± 3.3 103.2 ± 3.2 95.0 ± 1.8 96.6 ± 3.5 99.7 ± 2.2 100.6 ± 2.2 98.8 ± 3.0 100.1 ± 2.7
VO2 (L·min
− 1) 3.68 ± 0.26 3.75 ± 0.30 3.63 ± 0.25 3.45 ± 0.12 3.12 ± 0.27 3.50 ± 0.16 3.29 ± 0.18 3.02 ± 0.14 3.33 ± 0.28
VCO2 (L·min
−1) 3.75 ± 0.14 3.82 ± 0.16 3.77 ± 0.15 3.70 ± 0.16 3.35 ± 0.22 3.77 ± 0.19 3.91 ± 0.27 3.58 ± 0.22 3.94 ± 0.16
RER 1.10 ± 0.01 1.11 ± 0.03 1.13 ± 0.01 1.09 ± 0.02 1.07 ± 0.02 1.10 ± 0.01 1.11 ± 0.01 1.10 ± 0.02 1.12 ± 0.02
[La-]b (mmol·L
− 1) 10.7 ± 0.8 9.3 ± 0.6 10.0 ± 0.8 9.0 ± 1.0 8.4 ± 0.9 8.8 ± 1.1 9.4 ± 0.8 9.8 ± 0.9 9.1 ± 0.1
Data in Table 5 refers to the final 10-min split of the 30-min TT. Time points denoted by T1-T3. HR heart rate, RPE rating of perceived exertion, VE minute
ventilation, VO2 absolute oxygen uptake, VCO2 absolute carbon dioxide, RER respiratory exchange ratio, [La-]b post test blood lactate. No differences reported
Table 6 Average sprint performance data across T1-T3
βA1 βA2 PL
Variable T1 T2 T3 T1 T2 T3 T1 T2 T3
Distance (m) 165 ± 4 165 ± 4 164 ± 4 159 ± 3 160 ± 3 161 ± 4 163 ± 3 159 ± 2 163 ± 4
Power (W) 355.4 ± 13.8 355.4 ± 13.8 352.7 ± 14.5 333.5 ± 10.9 339.1 ± 12.1 342.2 ± 13.5 351.0 ± 13.1 335.0 ± 9.5 348.2 ± 13.9
Power (W·kg−1) 4.21 ± 0.06 4.21 ± 0.12 4.20 ± 0.13 4.16 ± 0.12 4.25 ± 0.15 4.27 ± 0.16 4.20 ± 0.08 4.06 ± 0.13 4.20 ± 0.11
HR (b·min− 1) 170 ± 5 177 ± 4 178 ± 3 170 ± 3 172 ± 5 174 ± 3 170 ± 5 168 ± 4 170 ± 4
RPE 9.0 ± 0.1 9.3 ± 0.1 9.3 ± 0.2 8.8 ± 0.2 9.0 ± 0.2 9.3 ± 0.2 8.7 ± 0.4 8.7 ± 0.4 9.1 ± 0.2
[La-]b 10.7 ± 1.0 9.6 ± 0.6 10.0 ± 0.9 9.1 ± 0.9 8.8 ± 1.0 9.2 ± 1.1 8.9 ± 0.9 8.9 ± 1.0 8.7 ± 0.9
Data refers to mean values across the 3 repeated sprints at time-points T1-T3 and experimental condition. No significant differences reported (P > 0.05)
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cycling, the smaller muscle mass engaged may be more
susceptible to localised muscular acidosis [44], providing a
more optimal environment for βA’s effects to augment.
This theory could help support previous research whereby
mean power was significantly increased during a 30-s
sprint following an endurance cycling event [10], propos-
ing that βA may only facilitate ergogenic effects when
there is an increased requirement to protect the ‘milieu
interieur’ from homeostatic perturbations caused by
supra-maximal levels of intracellular acidosis. However,
whilst the current cohorts [La−]b were clearly elevated
following each sprint bout, the mean [La−]b post time trial
and during associated sprint efforts for βA1 were not
significantly affected by βA consumption compared to PL,
possibly suggesting an absence of meaningful carnosine
facilitated buffering at the current dosage.
A novel aspect of this study was the inclusion of an
alternate day dosing strategy (at a matched total dose).
Previous research has suggested that the primary facilita-
tor of muscle carnosine concentration is the total dose
consumed, not factors such as baseline content or daily
dose [29]. The current data does not support this
hypothesis given the lack of significant findings in over-
all power, power to weight and distance covered at all
time-points for βA2. Likewise, despite an isolated
increase from T2-T3 in distance rowed during the first
10-min of the time trial, all other split data recorded
support a lack of effectiveness when βA is not consumed
daily. It is noteworthy, however, that although body
composition (including fat-free mass) was not signifi-
cantly different between groups, two individuals within
βA2 reported body-fat percentages below 10% in con-
trast to other participants. Furthermore, fat-free mass
ranged from 63.3–77.0 kg within βA2 (in contrast to
62.6–85.3 kg for βA1 and 60.3–85.0 kg for PL). Although
unlikely, based on individual performance differences
and average power (W and W·kg− 1), it is feasible that
one explanation for a lack of significant findings with
βA2 may have been influenced as a result of variances in
lean muscle mass.
Other reasons for variation caused by dosing may reside
in the pharmacokinetics of βA, with previous research
[45] exhibiting a large variation between participants when
given an equimolar amount (1400mg) of the supplement.
Alternatively, the consistency of daily consumption could
potentially produce a more favourable environment for
the bio-availability and subsequent augmentation of
carnosine. Future research is required to investigate both
the pharmacokinetics of βA beyond a single bolus and the
potential mechanistic pathways that facilitate more opti-
mal carnosine augmentation.
Limitations of this study include a lack of baseline
and/or temporal measures of skeletal muscle carnosine
concentrations. However, the dosing strategy utilised
was equal to or greater than preceding work that has
quantified muscle carnosine content [2, 46]. Further-
more, whilst [La−]b, RPE and HR were recorded
throughout the test, blood pH was not. Subsequently, it
must be conceded that the capacity to assess or infer
whether effects were associated with carnosine directed
(pH) buffering are limited. Additionally, due to a com-
monly reported side effect of βA (paraesthesia [1]), par-
ticipants within either experimental arm of this trial may
have become aware they were consuming the supple-
ment. However, instructions to consume small (800 mg)
individual doses, with food and regular verbal question-
ing at each visit indicated this was highly unlikely, with
no cases of paraesthesia being reported. Future research
should adopt dosing protocols that deliver βA in a
sustained-release (SR) formula which may negate this
issue [47, 48].
Beyond the delivery method of βA, previous
research demonstrated that at an average daily dose
of 5.2 g·day− 1 for four-weeks is not sufficient to maxi-
mise muscle carnosine content [3]. More recently this
claim has been supported by research that supplied
participants with 6.4 g·day− 1 of βA each day for 24
weeks, observing gene expression, muscle carnosine
content and cycling capacity (CCT110%) [49]. Inter-
estingly, this study’s primary observations was that
muscle carnosine increased in the experimental group
at all time-points with no change in PL, thus, investi-
gations into the effects of higher dose (> 4 g·day− 1
[14]) or duration (24+ weeks) interventions with βA
during endurance events are merited. Finally, whilst
βA may provide some ergogenic influence in young,
well-trained athletes, its effects within individuals who
have reduced carnosine content (untrained, vegan/
vegetarian or master’s athletes) [31] may be worth-
while, due to potentially amplified effects.
Conclusion
In conclusion, regardless of dose strategy, when
compared to placebo, βA does not enhance sustained
aerobic performance or subsequent high intensity
efforts. However, the within-group finding that daily
βA use increased 30-min rowing time trial perform-
ance warrants further investigation. The inclusion of
higher dosing strategies (> 2.4 g·day− 1) for longer
periods (> 28 days) should also be considered.
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